2026-04-14T06:09:08Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/601692025-12-22T13:45:52Zcom_2072_6col_2072_452952

urn:hdl:10230/60169 Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension Nathan, Steven D. Fernandes, Peter Psotka, Mitchell Vitulo, Patrizio Piccari, Lucilla Antoniou, Katerina Nikkho, Sylvia M. Stockbridge, Norman Clinical trial design Interstitial lung disease Pulmonary hypertension Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) is an attractive target for clinical trials of PH medications. There are many factors that need to be considered to prime such studies for success. The patient phenotype most likely to respond to the intervention requires weighing the extent of the parenchymal lung disease against the severity of the hemodynamic impairment. The inclusion criteria should not be too restrictive, thus enabling recruitment. The trial should be of sufficient duration to meet the chosen endpoint which should reflect how the patient feels, functions, or survives. This paper summarizes prior studies in PH-ILD and provides a framework of the type of studies to be considered. Inclusion criteria, clinical trial endpoints, and pharmacovigilance in the context of PH-ILD trials are also addressed. Through lessons learnt from prior studies, suggestions and guidance for future clinical trials in PH-ILD are also provided. 2024-05-16T06:26:18Z 2024-05-16T06:26:18Z 2022 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Pulm Circ. 2022 Oct 1;12(4):e12178 © 2022 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess Wiley